Organization
North Shore Health Hub, St Leonards, NSW, Australia
1 abstract
Abstract
Preliminary dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).Org: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, Genesis Care North Shore, North Shore Health Hub, St Leonards, NSW, Australia,